Measles Virus Reduction

Authors
Tristan Russell, PhD., Senior Scientific Officer
Facility
Airmid Healthgroup, Ireland
Download
Full Report

Objective

To assess the performance of the Defend 1050 in removing aerosolized Human parainfluenza type 3 (HPIV3) (renamed human respirovirus 3), a surrogate for Measles virus.

Methodology

The impact of the Defend 1050 air purifier on aerosolized HPIV3 (strain MK-3) was conducted in a 28.5 m3 environmental testing chamber. The test chamber was preconditioned to 20 ± 3 °C and 55 ± 5% relative humidity. During testing, the chamber air handling unit was shut down, which reduces the number of air changes to as close to zero as possible.

Results

The results achieved during the testing show that the Defend 1050 was able to reduce the concentration of HPIV3 by 99.87% in 20 - 30 minutes.

Defend 1050 achieved 99.87% reduction of measles surrogate

Contact

USA Headquarters
3540 Toringdon Way, Suite 200 Charlotte, NC  28277
1 866 508 1118
info@wellairsolutions.com

Ireland Headquarters
DCU Innovation Campus
Old Finglas Road
Glasnevin, Dublin D11 KXN4
+353 1 907 2750
info@wellairsolutions.com

Contact WellAir

Social

Partners